MiniMed Group (NASDAQ:MMED – Get Free Report) was upgraded by stock analysts at Zacks Research to a “hold” rating in a report released on Thursday,Zacks.com reports.
A number of other equities research analysts also recently issued reports on MMED. Deutsche Bank Aktiengesellschaft assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $20.00 price target on the stock. Wall Street Zen raised shares of MiniMed Group to a “hold” rating in a research note on Saturday, March 14th. Piper Sandler assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They set a “neutral” rating and a $16.00 price target on the stock. Wells Fargo & Company assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They set an “overweight” rating and a $26.00 price target on the stock. Finally, Bank of America initiated coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They set a “buy” rating and a $27.00 price target on the stock. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.
View Our Latest Research Report on MMED
MiniMed Group Stock Up 0.9%
About MiniMed Group
We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.
Recommended Stories
Receive News & Ratings for MiniMed Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiniMed Group and related companies with MarketBeat.com's FREE daily email newsletter.
